COVID Vaccines: What FDA Isn’t Talking About Ahead Of Upcoming Advisory Panel

From next-generation vaccine technology to safety data and global harmonization, what isn’t in the Vaccines and Related Biological Products Advisory Committee preview documents and on the 26 January meeting agenda may be just as important as what is.  

mrna covid vaccines
What’s not on the 26 January Vaccine Advisory Panel Agenda Is As Notable As What Is • Source: Shutterstock

The US Food and Drug Administration’s next COVID-19 vaccine advisory panel isn’t designed to push the country towards new types of vaccines for the virus which continues to plague the world more than three years after its first appearance.

The role of next generation vaccine technology was one of a few notable topics missing from the 26 January Vaccines...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers